BCL-2 Inhibition via Venetoclax at ART Initiation Induces Long-Term Reduction of the Intact SIV Reservoir
Preprint
- 14 July 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
The anti-apoptotic molecule BCL-2 favors the maintenance of the CD4+ T-cell reservoir during Human Immunodeficiency Virus (HIV) infection. We investigated directly in-vivo whether BCL-2 inhibition using venetoclax at the initiation of antiretroviral therapy (ART) would reduce the size of the viral reservoir. Twenty-four SIVmac239-infected rhesus macaques (RMs) initiated ART at day 14 post-infection (p.i.), alone or with a 10-day treatment with venetoclax or venetoclax plus CD8α depletion, and followed up to day 294 p.i. A rapid, statistically significant, and sustained reduction in the intact SIV reservoir was observed in venetoclax-treated RMs in blood and lymph nodes (LNs). This reduction was driven by reduced survival and depletion of CD4+ T-cell subsets that critically contribute to the reservoir. CD4+ T-cells that persisted after venetoclax treatment exhibited elevated per-cell levels of BCL-2, reduced expression of pro-apoptotic molecules such as PUMA, increased expression of additional anti-apoptotic molecules, including BCL-xL, and a partial reduction in apoptotic sensitivity in ex vivo assays. These findings provide mechanistic insights for the venetoclax-induced pro-cell death changes in CD4+ T-cells, support the rationale for extended venetoclax dosing, and suggest that combining BCL-2 inhibition with agents targeting additional anti-apoptotic molecules can enhance clearance of the viral reservoir in HIV cure strategies.Keywords
All Related Versions
- Version 1, 2025-07-14, Research Square
- Published version: Nature Microbiology, 11 (10), 2707.
This publication has 50 references indexed in Scilit:
- Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized miceCell Reports Medicine, 2023
- A20 and Cell Death-driven InflammationTrends in Immunology, 2020
- BCL10 in cell survival after DNA damageClinica Chimica Acta, 2019
- The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 InfectionsCell Host & Microbe, 2019
- Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T CellsImmunity, 2018
- Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directionsBlood Cancer Journal, 2017
- DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAXCell Death & Disease, 2015
- ING1 induces apoptosis through direct effects at the mitochondriaCell Death & Disease, 2013
- Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogmaLaboratory Investigation, 2009
- Smad7 induces tumorigenicity by blocking TGF-β-induced growth inhibition and apoptosisExperimental Cell Research, 2005